The impact of a high-grade glioma on everyday life: A systematic review from the patient’s and caregiver’s perspective

Wendy Sterckx(KU Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven), Marleen Decruyenaere(KU Leuven), Annemarie Coolbrandt(KU Leuven), Bernadette Dierckx de Casterlé(KU Leuven), Anne Mees(KU Leuven), Koen Van den Heede(Belgian Health Care Knowledge Centre (KCE)), Sonja Borgenon(KU Leuven)

European Journal of Oncology Nursing

May 31, 2012

10.1016/j.ejon.2012.04.006

Cited by 140

Related Papers

Patient safety, satisfaction, and quality of hospital care: cross sectional surveys of nurses and patients in 12 countries in Europe and the United States

|BMJ|2012|2k

Lomustine and Bevacizumab in Progressive Glioblastoma

|New England Journal of Medicine|2017|994

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

|Journal of Clinical Oncology|2009|573

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

|The Lancet Oncology|2016|504

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

|Journal of Clinical Oncology|2010|445